First application of the Automated QUantitative Analysis (AQUA) technique to quantify PTEN protein expression in ovarian cancer: A correlative study of NCIC CTG OV.16

Gynecologic Oncology
J I WeberpalsD P LeBrun

Abstract

Platinum resistance is a dominant cause of poor outcomes in advanced ovarian cancer (OC). A mechanism of platinum resistance is the inhibition of apoptosis through phosphatidylinositol 3 kinase (PI3K) pathway activation. The role of phosphatase and tensin homolog (PTEN), a negative regulator of this pathway, as a tumor biomarker is unclear. Quantitative analysis of PTEN expression as an alternative to immunohistochemistry has not been considered. In 238 patient tumors from the NCIC-CTG trial OV.16, PTEN protein expression was quantified by Automated QUantitative Analysis (AQUA). Cox model was used to study the association between PTEN expression and clinical outcomes using a minimum p-value approach in univariate analysis. Multivariate analysis was used to adjust for clinical and pathological parameters. PTEN scores (range 13.9-192.3) of the 202 samples that passed quality control were analyzed. In univariate analysis, there was a trend suggesting an association between PTEN expression by AQUA as a binary variable (low ≤61 vs high >61) and progression free survival (HR=0.77, p=0.083), and in multivariate analysis, this association approached significance (HR=0.74, p=0.059). The relationship between quantitative PTEN expression ...Continue Reading

References

Sep 5, 2002·International Journal of Cancer. Journal International Du Cancer·Yasunobu KanamoriNaoki Terakawa
Dec 22, 2005·Journal of the National Cancer Institute·Anthony McCabeDavid L Rimm
Dec 24, 2005·The Journal of Biological Chemistry·Francis EdwinTarun B Patel
Jul 1, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Edith A PerezRobert B Jenkins
Aug 26, 2006·Breast Cancer Research and Treatment·Lisa M McShaneUNKNOWN Statistics Subcommittee of NCI-EORTC Working Group on Cancer Diagnostics
Mar 21, 2007·Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology·Ziwei YuAmanda Psyrri
Mar 11, 2009·Frontiers in Bioscience (Landmark Edition)·Daniel G RosenJinsong Liu
Jan 6, 2010·EMBO Molecular Medicine·Ana M Mendes-PereiraAlan Ashworth
Jun 16, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Robert C Bast, Gordon B Mills
Oct 15, 2010·Science Translational Medicine·Konstantin J DedesJorge S Reis-Filho
Mar 4, 2011·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J I WeberpalsE A Eisenhauer
Jul 28, 2011·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·Ingirídur Skírnisdóttir, Tomas Seidal
Apr 18, 2013·International Journal of Molecular Sciences·Zachary C Dobbin, Charles N Landen
Jan 6, 2015·Chinese Journal of Cancer·Bianca CheaibAlexandra Leary
Mar 13, 2015·Frontiers in Oncology·Michele MilellaLudovica Ciuffreda
May 29, 2015·Nature·Ann-Marie PatchDavid D L Bowtell
Jul 15, 2015·International Journal of Gynecological Pathology : Official Journal of the International Society of Gynecological Pathologists·Rania M BakkarRussell R Broaddus

❮ Previous
Next ❯

Citations


❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Epigenetics & Metabolism (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on the relationship between cell metabolism, epigenetics and tumor differentiation.

Cancer Epigenetics and Senescence (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may be involved in regulating senescence in cancer cells. This feed captures the latest research on cancer epigenetics and senescence.

AKT Pathway

This feed focuses on the AKT serine/threonine kinase, which is an important signaling pathway involved in processes such as glucose metabolism and cell survival.

Breast Cancer: BRCA1 & BRCA2

Mutations involving BRCA1, found on chromosome 17, and BRCA2, found on chromosome 13, increase the risk for specific cancers, such as breast cancer. Discover the last research on breast cancer BRCA1 and BRCA2 here.

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis